Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorMecklenburg, J. (Jasper)-
dc.creatorRaffaelli, B. (Bianca)-
dc.creatorNeeb, L. (Lars)-
dc.creatorSanchez-del-Río, M. (Margarita)-
dc.creatorRuiz-de-la-Torre, E. (Elena)-
dc.date.accessioned2023-05-30T07:07:40Z-
dc.date.available2023-05-30T07:07:40Z-
dc.date.issued2020-
dc.identifier.citationMecklenburg, J. (Jasper); Raffaelli, B. (Bianca); Neeb, L. (Lars); et al. "The potential of lasmiditan in migraine". Therapeutic Advances in Neurological Disorders. 13, 2020, 1 - 11es
dc.identifier.issn1756-2856-
dc.identifier.urihttps://hdl.handle.net/10171/66459-
dc.description.abstractLasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT1F) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has recently approved lasmiditan for the acute treatment of migraine in adults based on positive results of two pivotal phase III trials, which showed a significant difference to placebo in the proportion of patients achieving total migraine freedom within 2h. More patients with lasmiditan achieved headache freedom and, in addition, freedom from the most bothersome symptom, that is, photophobia, than with placebo. Treatmentrelated side effects seem to be related to the rapid penetration of the drug into the brain and include dizziness, paresthesia and drowsiness, mostly of mild to moderate intensity. Interim results from an ongoing long-term phase III trial suggest a decrease in the frequency of adverse events after multiple lasmiditan use. Lasmiditan is a promising acute anti-migraine therapy, in particular for patients with cardiovascular risk factors, contraindications, or unwanted side effects to triptans.es_ES
dc.language.isoenges_ES
dc.publisherSAGE Publicationses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectCGRPes_ES
dc.subjectCluster headachees_ES
dc.subjectDitanes_ES
dc.subjectDizzinesses_ES
dc.subject5-HT1Fes_ES
dc.subjectLasmiditanes_ES
dc.subjectMigrainees_ES
dc.titleThe potential of lasmiditan in migrainees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).es_ES
dc.identifier.doi10.1177/1756286420967847-
dadun.citation.endingPage11es_ES
dadun.citation.publicationNameTherapeutic Advances in Neurological Disorderses_ES
dadun.citation.startingPage1es_ES
dadun.citation.volume13es_ES
dc.identifier.pmid33403005-

Ficheros en este ítem:
Vista previa
Fichero
1756286420967847.pdf
Descripción
Tamaño
323 kB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.